These findings were corroborated by a recent phase 1/2 clinical trial, which reported outcomes for five patients with severe WAS who received gene therapy using a self-inactivating lentiviral vector expressing human WAS cDNA.371 All patients were alive and in good health, with sustained multilineage vector gene marking. This evidence concerns the gene WAS and Wiskott-Aldrich syndrome.